Axonis Therapeutics, Inc., a Cambridge, Mass.-based biotechnology company advancing breakthrough research to develop therapies for neurological disorders, secured an additional $5m in funding.
The round was led by Alexandria Venture Investments with participation from R3 Bio, BoxOne Ventures and Civilization Ventures and the Christopher & Dana Reeve Foundation and Spinal Research.
The company intends to use the funds to advance its novel neuromodulating technology into the clinic.
Led by Joanna Stanicka, PhD, CEO, and Shane Hegarty, PhD, Chief Scientific Officer, Axonis Therapeutics is advancing breakthrough research to develop therapies for neurological disorders. The company’s pipeline includes neuron-reviving therapeutics that enable an intrinsic ability of central nervous system (CNS) neurons to resist degeneration, restore excitation/inhibition balance and regenerate. The company’s targeted indications include spinal cord injury and epilepsy, as well as broader neurodegenerative conditions. Most recently, Axonis completed proof-of-concept pre-clinical studies on the upmodulation of the KCC2 protein function that reactivates spared neural tissue at the site of spinal cord injury. In addition to CNS injuries, the therapeutic benefits of KCC2 enhancement have also been shown in animal models to address chronic pain, epilepsy, Rett syndrome and others.
FinSMEs
15/07/2021